Ruxolitinib CAS: 941678-49-5
MF: C17H18N6
MW: 306.37

Ruxolitinib (CAS 941678-49-5)

Ruxolitinib | CAS 941678-49-5 is rated 5.0 out of 5 by 1.
  • y_2021, m_6, d_12, h_18
  • bvseo_bulk, prod_bvrr, vn_bulk_3.0.17
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_364729, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getAggregateRating, 138ms
  • REVIEWS, PRODUCT
loading
5
1
4
0
3
0
2
0
1
0
Alternate Names: Ruxolitinib is also known as INCB 018424.
Application: Ruxolitinib is a potent Janus-associated kinase (JAK) inhibitor, selective to JAK1, JAK2, and JAK3.
CAS Number: 941678-49-5
Purity: ≥98%
Molecular Weight: 306.37
Molecular Formula: C17H18N6
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data (including water content).
loading

Ruxolitinib is a JAK inhibitor of JAK1 (IC50 = 2.7 nM), JAK2 (IC50 = 4.5 nM), and JAK3 (IC50 = 322 nM). JAKs, or Janus-associated kinases, are tyrosine kinases found in the cytoplasm that are known to activate the signaling of certain growth factor receptors and cytokines. As a potent ATP mimetic, Ruxolitinib inhibits both JAK1 and JAK2 with IC50 values of 2.7 and 4.5 nM, respectively and is relatively less selective for JAK3 (IC50 = 322 nM). Ruxolitinib can block interleukin-6 (IL-6) signaling (IC50 = 281 nM) and proliferation of JAK2V617F+ Ba/F3 cells (IC50 = 127 nM). In primary cultures, ruxolitinib preferentially suppresses erythroid progenitor colony formation from JAK2V617F+ polycythemia vera patients (IC50 = 67 nM) versus healthy donors (IC50 > 400 nM).


References

1. Leonard, W.J., and O′Shea, J.J.JAKS AND STATS: Biological implications. Annual Reviews of Immunology 16, 293-322 (1998).
2. Yamaoka, K., Saharinen, P., Pesu, M., et al.The Janus kinases (Jaks). Genome Biol. 5(12), 253 (2004).
3. Verstovsek, S.Therapeutic potential of JAK2 inhibitors. Hematology Am.Soc.Hematol.Educ.Program 2009(1), 636-642 (2009).
4. Quintás-Cardama, A., Vaddi, K., Liu, P., et al.Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: Therapeutic implications for the treatment of myeloproliferative neoplasms. Blood 115(15), 3109-3117 (2010).

Appearance :
Powder
Physical State :
Solid
Solubility :
Soluble in DMSO (61 mg/ml at 25° C), ethanol (15 mg/ml) with warming, DMF (~5 mg/ml), water (<1 mg/ml at 25° C), and methanol.
Storage :
Store at -20° C
Melting Point :
86-89° C
Boiling Point :
~592.6° C at 760 (Predicted)
Density :
~1.4 g/cm3 (Predicted)
Refractive Index :
n20D 1.75 (Predicted)
Optical Activity :
α20D -8.0, c = 0.3 in methanol
IC50 :
JAK1: IC50 = 0.8 nM (human); JAK2: IC50 = 2.8 nM (human); JAK3: IC50 = 10.7 nM (human); Tyk 2: IC50 = 19 nM (human); JAK3/JAK1: IC50 = 23 nM (human)
Ki Data :
JAK1: Ki= 0.09 nM (human); JAK2: Ki= 0.1 nM (human); Tyk 2: Ki= 0.5 nM (human); JAK3: Ki= 3.2 nM (human)
pK Values :
pKa: 11.63 (Predicted), pKb: 3.67 (Predicted)
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
PubChem CID :
MDL Number :
MFCD12031592
SMILES :
C1CCC(C1)[[email protected]@H](CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3

Download SDS (MSDS)

Certificate of Analysis

Adobe Acrobat Reader is required to reliably view,
print and comment on PDF documents

Ruxolitinib (CAS 941678-49-5)  Product Citations

See how others have used Ruxolitinib (CAS 941678-49-5). Click on the entry to view the PubMed entry .

Citations 1 to 10 of 15 total

PMID: # 32937365  Verma, N.|Vinik, Y.|Saroha, A.|Nair, NU.|Ruppin, E.|Mills, G.|Karn, T.|Dubey, V.|Khera, L.|Raj, H.|Maina, F.|Lev, S.| et al. 2020. Sci Adv. 6:

PMID: # 31992798  Qadir, AS.|Stults, AM.|Murmann, AE.|Peter, ME.| et al. 2020. Sci Rep. 10: 1310.

PMID: # 31391303  2019. Proc. Natl. Acad. Sci. U.S.A. 116: 17399-17408.

PMID: # 30891766  He, Z. et al. 2019. Ann. N. Y. Acad. Sci. 1442: 128-137.

PMID: # 29907868  Ménoret, A.|Buturla, JA.|Xu, MM.|Svedova, J.|Kumar, S.|Rathinam, VAK.|Vella, AT.| et al. 2018. Mucosal Immunol. 11: 1398-1407.

PMID: # 30012499  Mesbahi, Y.|Zekri, A.|Ghaffari, SH.|Tabatabaie, PS.|Ahmadian, S.|Ghavamzadeh, A.| et al. 2018. Eur. J. Pharmacol. 834: 65-76.

PMID: # 30348790  2018. Eur. J. Pharmacol. 834: 65-76.

PMID: # 30247637  2018. Mol. Hum. Reprod. 24: 533-542.

PMID: # 26573834  Tsurutani, N. et al. 2016. Journal of immunology (Baltimore, Md. : 1950). 196: 124-34.

PMID: # 27035543  Jinushi, M. et al. 2016. Viral immunology. 29: 296-306.

Citations 1 to 10 of 15 total

Puo essere utilizzato per malati di policitemia vera?

Asked by: francesco
Grazie per la domanda. Tutti i reagenti chimici e gli anticorpi offerti dalla Santa Cruz Biotechnology, Inc. sono forniti solo per ricerca di laboratorio in vitro (in-vitro RUO). I prodotti non sono destinati ad uso diagnostico o terapeutico e non devono essere utilizzati su animali o persone. Thank you for your question. All chemicals and antibodies offered by Santa Cruz Biotechnology, Inc. are supplied for laboratory in-vitro research use only (in-vitro RUO). The products are not intended for diagnostic or therapeutic use and must not be applied to animals or humans.
Answered by: Technical Support Europe
Date published: 2016-10-11
  • y_2021, m_6, d_12, h_18CST
  • bvseo_bulk, prod_bvqa, vn_bulk_3.0.17
  • cp_1, bvpage1
  • co_hasquestionsanswers, tq_1
  • loc_en_US, sid_364729, prod, sort_[SortEntry(order=LAST_APPROVED_ANSWER_SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getContent, 148ms
  • QUESTIONS, PRODUCT
Rated 5 out of 5 by from Alimam et al Alimam et al. (PubMed ID 26343888) used Ruxolitinib to inhibit JAK1/2 in low-risk myelofibrosis patients. -SCBT Publication Review
Date published: 2015-02-27
  • y_2021, m_6, d_12, h_18
  • bvseo_bulk, prod_bvrr, vn_bulk_3.0.17
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_364729, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getReviews, 15ms
  • REVIEWS, PRODUCT

Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2021 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.